- Home
- AB vs IOVA Comparison
AB vs IOVA Comparison
Compare AB & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AB
- IOVA
- Stock Information
- Founded
- AB 1987
- IOVA 2007
- Country
- AB United States
- IOVA United States
- Employees
- AB N/A
- IOVA N/A
- Industry
- AB Investment Managers
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AB Finance
- IOVA Health Care
- Exchange
- AB Nasdaq
- IOVA Nasdaq
- Market Cap
- AB 4.1B
- IOVA 2.6B
- IPO Year
- AB 1988
- IOVA N/A
- Fundamental
- Price
- AB $35.34
- IOVA $5.89
- Analyst Decision
- AB Strong Buy
- IOVA Strong Buy
- Analyst Count
- AB 5
- IOVA 9
- Target Price
- AB $43.00
- IOVA $23.33
- AVG Volume (30 Days)
- AB 434.5K
- IOVA 8.2M
- Earning Date
- AB 02-04-2025
- IOVA 02-26-2025
- Dividend Yield
- AB 8.70%
- IOVA N/A
- EPS Growth
- AB 57.32
- IOVA N/A
- EPS
- AB 3.49
- IOVA N/A
- Revenue
- AB $134,096,000.00
- IOVA $90,858,000.00
- Revenue This Year
- AB N/A
- IOVA $13,758.71
- Revenue Next Year
- AB $6.95
- IOVA $171.20
- P/E Ratio
- AB $10.14
- IOVA N/A
- Revenue Growth
- AB N/A
- IOVA 12751.20
- 52 Week Low
- AB $30.57
- IOVA $5.77
- 52 Week High
- AB $38.96
- IOVA $18.33
- Technical
- Relative Strength Index (RSI)
- AB 43.25
- IOVA 26.25
- Support Level
- AB $35.13
- IOVA $5.77
- Resistance Level
- AB $37.77
- IOVA $8.15
- Average True Range (ATR)
- AB 0.89
- IOVA 0.44
- MACD
- AB -0.16
- IOVA -0.11
- Stochastic Oscillator
- AB 7.27
- IOVA 5.04
About AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (42% of assets under management), retail (41%), and private (17%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of October 2024, AB had $793 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (42%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.